SecSonar.com

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ACADIA Pharmaceuticals Inc. (ACAD) is a Biotechnology company based in US with a market capitalization of $3.7B. Revenue grew 11.9% year-over-year and the company generated $105.1M in free cash flow. This page tracks ACAD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 653 employees · IPO May 27, 2004

Valuation

Valuation & price

$22.09 · as of May 15, 2026 · -21.3% vs 52w high

9.7

P/E ratio

Latest-FY diluted EPS

3.04

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$28.06$24.06$20.06Jul 25Dec 25Jul 26Jul 7, 25$20.88Jul 9, 25$21.57Jul 11, 25$20.98Jul 15, 25$22.01Jul 17, 25$22.55Jul 21, 25$22.28Jul 23, 25$23.27Jul 25, 25$23.25Jul 29, 25$22.63Jul 31, 25$23.83Aug 4, 25$24.04Aug 6, 25$23.80Aug 11, 25$24.82Aug 13, 25$25.13Aug 15, 25$25.33Aug 19, 25$24.97Aug 21, 25$24.79Aug 25, 25$25.32Aug 27, 25$26.57Aug 29, 25$25.99Sep 3, 25$25.72Sep 5, 25$25.26Sep 9, 25$24.84Sep 11, 25$24.20Sep 16, 25$23.96Sep 18, 25$24.76Sep 22, 25$24.53Sep 24, 25$21.26Sep 26, 25$21.05Sep 30, 25$21.34Oct 2, 25$21.38Oct 6, 25$21.59Oct 8, 25$21.31Oct 10, 25$20.06Oct 14, 25$20.36Oct 16, 25$20.62Oct 21, 25$21.27Oct 23, 25$21.73Oct 27, 25$22.99Oct 29, 25$22.53Oct 31, 25$22.70Nov 4, 25$21.85Nov 6, 25$21.65Nov 10, 25$22.20Nov 12, 25$24.13Nov 14, 25$24.02Nov 18, 25$23.80Nov 20, 25$22.90Nov 25, 25$24.39Nov 28, 25$25.04Dec 2, 25$25.43Dec 4, 25$26.55Dec 8, 25$26.76Dec 10, 25$26.81Dec 12, 25$27.15Dec 16, 25$26.80Dec 18, 25$26.60Dec 22, 25$28.06Dec 24, 25$27.87Dec 29, 25$27.26Jan 2, 26$26.29Jan 6, 26$26.94Jan 8, 26$26.91Jan 12, 26$26.59Jan 14, 26$26.86Jan 16, 26$25.99Jan 21, 26$26.76Jan 23, 26$26.84Jan 27, 26$26.20Jan 29, 26$25.70Feb 2, 26$26.13Feb 4, 26$24.23Feb 9, 26$23.22Feb 11, 26$22.47Feb 13, 26$22.03Feb 18, 26$23.20Feb 20, 26$23.99Feb 24, 26$24.59Feb 26, 26$24.64Mar 2, 26$22.81Mar 4, 26$23.39Mar 6, 26$22.16Mar 10, 26$22.54Mar 12, 26$21.27Mar 17, 26$20.90Mar 19, 26$20.72Mar 23, 26$20.99Mar 25, 26$22.01Mar 27, 26$20.75Mar 31, 26$22.26Apr 2, 26$22.20Apr 7, 26$22.09Apr 9, 26$22.57Apr 13, 26$21.46Apr 15, 26$21.76Apr 17, 26$22.17Apr 22, 26$22.24Apr 24, 26$21.96Apr 28, 26$22.67Apr 30, 26$22.45May 4, 26$22.19May 6, 26$21.48May 8, 26$22.40May 12, 26$21.72May 14, 26$22.09May 18, 26$20.69May 20, 26$20.95May 22, 26$21.10May 28, 26$21.63Jun 1, 26$21.52Jun 3, 26$21.43Jun 5, 26$21.56Jun 9, 26$21.84Jun 11, 26$21.39Jun 15, 26$21.27Jun 17, 26$21.60Jun 22, 26$22.09Jun 24, 26$23.36Jun 26, 26$25.32Jul 2, 26$25.97
$20.0652-week range$28.06
Loading valuation history…

Fundamentals

Key fundamentals

$3.7B

Market cap

11.9%

Revenue growth (YoY)

91.7%

Gross margin

$105.1M

Free cash flow (USD)

-$767.5M

Net debt

Net cash position

2.2%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$17.3MFY 2017$124.9MFY 2018$223.8MFY 2019$339.1MFY 2020$441.8MFY 2021$484.1MFY 2022$517.2MFY 2023$726.4MFY 2024$957.8MFY 2025$1.1B
$17.3M$1.1B

Free cash flow by year

2016 → 2025

FY 2016$-219.9MFY 2017$-218.7MFY 2018$-169.6MFY 2019$-152.3MFY 2020$-143.8MFY 2021$-126.8MFY 2022$-114.0MFY 2023$-23.3MFY 2024$157.2MFY 2025$105.1M
-$219.9M$105.1M

Gross margin by year

2021 → 2025

FY 202196.0%FY 202298.0%FY 202393.7%FY 202491.5%FY 202591.7%
96.0%91.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $298K · 10b5-1 PlanKihara James · PRINCIPAL ACCOUNTING OFFICER · $297.9KJun 29, 2026Filing
  • 8-K eventEquity Incentive Plan AdoptedMay 29, 2026Filing
  • Insider sellInsider Sell $114KKihara James · PRINCIPAL ACCOUNTING OFFICER · $114.4KMay 27, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Insider sellInsider Sell $76K · 10b5-1 PlanSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER · $76.4KMay 5, 2026Filing
  • Insider sellInsider Sell $29K · 10b5-1 PlanKihara James · PRINCIPAL ACCOUNTING OFFICER · $29KMay 5, 2026Filing
  • 8-K eventExecutive RetirementMay 1, 2026Filing
  • Insider sellInsider Sell $23K · 10b5-1 PlanKihara James · PRINCIPAL ACCOUNTING OFFICER · $22.9KApr 7, 2026Filing
  • Insider sellInsider Sell $60K · 10b5-1 PlanSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER · $60.1KApr 7, 2026Filing

Questions

Frequently asked questions

What is ACADIA Pharmaceuticals Inc.'s market cap?

ACADIA Pharmaceuticals Inc. (ACAD) has a market capitalization of $3.7B.

What is ACAD's P/E ratio?

ACAD trades at a price-to-earnings ratio of 9.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ACAD's price-to-book (P/B) ratio?

ACAD trades at 3.04 times book value per share.

Are insiders buying ACAD stock?

SEC Form 4 filings show no open-market insider buys at ACADIA Pharmaceuticals Inc. in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

VCYT

Veracyte, Inc.

$3.8B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

DNTH

Dianthus Therapeutics, Inc.

$3.8B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.